临床试验数据共享:试验数据集匿名化的实践指南
非商业资助方日益要求试验者在主要分析完成后开放试验数据,同时需兼顾参与者身份识别风险及法律法规要求。作者依据MRC HTMR良好实践指南,对一项刚完成试验的数据集进行匿名化,按直接、间接和冗余标识符分类采用不同匿名方法,建立受控访问模式并实施数据发布流程,最终形成定制的匿名化数据集。
要点
- 依据MRC HTMR良好实践指南对一项已完成试验的数据集实施匿名化。
- 变量按直接、间接和冗余标识符分类,并采用不同匿名化方法。
- 建立受控访问模式,实施数据发布流程并完成匿名化数据集检查。
核心结论
- 作者实施了一套实用的数据匿名化方案,为一项刚完成的试验生成了定制的匿名化数据集。
- 作者在流程效率、匿名性与数据利用之间的平衡以及未来应开展的工作方面获得了有益经验。
研究设计与样本
- 依据医学研究理事会试验方法学研究枢纽(MRC HTMR)资助工作形成的良好实践指南,对一项近期完成试验的数据集进行匿名化。
- 以该试验为例,展示数据集匿名化的实践指南,并描述可应用于其他试验数据集的规则。
- 描述当试验数据可自由获取与仅可在特定许可和数据使用协议下访问时,匿名化规则可能存在的差异。
主要发现
- 遵循良好实践指南,作者成功创建了临床试验数据共享的受控访问模式。
- 数据按个案评估,将变量分类为直接、间接和冗余标识符,并根据标识符类型分配不同的匿名化方法。
- 创建了最终数据集并应用了匿名化数据集检查,最后实施数据发布程序以完成整个流程。
临床怎么用
- 可参照该实践指南,将试验数据集中的变量按直接、间接和冗余标识符分类,并据此采用不同的匿名化方法。
- 可根据数据开放程度(自由获取或需特定许可与数据使用协议)调整匿名化规则。
- 匿名化流程可包括创建最终数据集、检查匿名化数据集并实施数据发布程序。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There is an increasing demand by non-commercial funders that trialists should provide access to trial data once the primary analysis is completed. This has to take into account concerns about identifying individual trial participants, and the legal and regulatory requirements. METHODS: Using the good practice guideline laid out by the work funded by the Medical Research Council Hubs for Trials Methodology Research (MRC HTMR), we anonymised a dataset from a recently completed trial. Using this example, we present practical guidance on how to anonymise a dataset, and describe rules that could be used on other trial datasets. We describe how these might differ if the trial was to be made freely available to all, or if the data could only be accessed with specific permission and data usage agreements in place. RESULTS: Following the good practice guidelines, we successfully created a controlled access model for trial data sharing. The data were assessed on a case-by-case basis classifying variables as direct, indirect and superfluous identifiers with differing methods of anonymisation assigned depending on the type of identifier. A final dataset was created and checks of the anonymised dataset were applied. Lastly, a procedure for release of the data was implemented to complete the process. CONCLUSIONS: We have implemented a practical solution to the data anonymisation process resulting in a bespoke anonymised dataset for a recently completed trial. We have gained useful learnings in terms of efficiency of the process going forward, the need to balance anonymity with data utilisation and future work that should be undertaken.
引用
- Keerie C, Tuck C, Milne G, et al. Data sharing in clinical trials - practical guidance on anonymising trial datasets. Trials. 2018. PMID: 29321053. doi:10.1186/s13063-017-2382-9
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。